689 related articles for article (PubMed ID: 26398702)
21. N-terminal and C-terminal cytosine deaminase domain of APOBEC3G inhibit hepatitis B virus replication.
Lei YC; Tian YJ; Ding HH; Wang BJ; Yang Y; Hao YH; Zhao XP; Lu MJ; Gong FL; Yang DL
World J Gastroenterol; 2006 Dec; 12(46):7488-96. PubMed ID: 17167839
[TBL] [Abstract][Full Text] [Related]
22. Molecular targets for therapy of hepatitis B virus-induced hepatocellular carcinoma.
Tharayil VS; Roberts LR
Minerva Gastroenterol Dietol; 2006 Dec; 52(4):387-406. PubMed ID: 17108869
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis B virus pre-S/S variants in liver diseases.
Chen BF
World J Gastroenterol; 2018 Apr; 24(14):1507-1520. PubMed ID: 29662289
[TBL] [Abstract][Full Text] [Related]
24. Conceptual models for the initiation of hepatitis B virus-associated hepatocellular carcinoma.
Tu T; Budzinska MA; Shackel NA; Jilbert AR
Liver Int; 2015 Jul; 35(7):1786-800. PubMed ID: 25640596
[TBL] [Abstract][Full Text] [Related]
25. Hepatitis B virus pathogenesis: Fresh insights into hepatitis B virus RNA.
Sekiba K; Otsuka M; Ohno M; Yamagami M; Kishikawa T; Suzuki T; Ishibashi R; Seimiya T; Tanaka E; Koike K
World J Gastroenterol; 2018 Jun; 24(21):2261-2268. PubMed ID: 29881235
[TBL] [Abstract][Full Text] [Related]
26. Hepatitis B virus pre-S2 mutant large surface protein inhibits DNA double-strand break repair and leads to genome instability in hepatocarcinogenesis.
Hsieh YH; Chang YY; Su IJ; Yen CJ; Liu YR; Liu RJ; Hsieh WC; Tsai HW; Wang LH; Huang W
J Pathol; 2015 Jul; 236(3):337-47. PubMed ID: 25775999
[TBL] [Abstract][Full Text] [Related]
27. A3G-induced mutations show a low prevalence and exhibit plus-strand regional distribution in hepatitis B virus DNA from patients with non-hepatocellular carcinoma (HCC) and HCC.
Ren F; Li W; Zhao S; Wang L; Wang Q; Li M; Xiang A; Guo Y
J Med Virol; 2021 Jun; 93(6):3672-3678. PubMed ID: 32779759
[TBL] [Abstract][Full Text] [Related]
28. Hepatitis B viral factors and clinical outcomes of chronic hepatitis B.
Lin CL; Kao JH
J Biomed Sci; 2008 Mar; 15(2):137-45. PubMed ID: 18058038
[TBL] [Abstract][Full Text] [Related]
29. The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets.
Ringelhan M; O'Connor T; Protzer U; Heikenwalder M
J Pathol; 2015 Jan; 235(2):355-67. PubMed ID: 25196558
[TBL] [Abstract][Full Text] [Related]
30. Hepatocellular carcinoma and hepatitis B virus.
Chan HL; Sung JJ
Semin Liver Dis; 2006 May; 26(2):153-61. PubMed ID: 16673293
[TBL] [Abstract][Full Text] [Related]
31. Factors predicting occurrence and prognosis of hepatitis-B-virus-related hepatocellular carcinoma.
Han YF; Zhao J; Ma LY; Yin JH; Chang WJ; Zhang HW; Cao GW
World J Gastroenterol; 2011 Oct; 17(38):4258-70. PubMed ID: 22090781
[TBL] [Abstract][Full Text] [Related]
32. AID and APOBECs as Multifaceted Intrinsic Virus-Restricting Factors: Emerging Concepts in the Light of COVID-19.
Meshcheryakova A; Pietschmann P; Zimmermann P; Rogozin IB; Mechtcheriakova D
Front Immunol; 2021; 12():690416. PubMed ID: 34276680
[TBL] [Abstract][Full Text] [Related]
33. The cytidine deaminases AID and APOBEC-1 exhibit distinct functional properties in a novel yeast selectable system.
Krause K; Marcu KB; Greeve J
Mol Immunol; 2006 Feb; 43(4):295-307. PubMed ID: 15963568
[TBL] [Abstract][Full Text] [Related]
34. Uracil DNA glycosylase counteracts APOBEC3G-induced hypermutation of hepatitis B viral genomes: excision repair of covalently closed circular DNA.
Kitamura K; Wang Z; Chowdhury S; Simadu M; Koura M; Muramatsu M
PLoS Pathog; 2013; 9(5):e1003361. PubMed ID: 23696735
[TBL] [Abstract][Full Text] [Related]
35. Association of a potential functional pre-miR-218 polymorphism and its interaction with hepatitis B virus mutations with hepatocellular carcinoma risk.
Han Y; Pu R; Han X; Zhao J; Li W; Yin J; Zhang Y; Shen Q; Xie J; Zhang Q; Jiang S; Li J; Zhang H; Wang H; Cao G
Liver Int; 2014 May; 34(5):728-36. PubMed ID: 24118778
[TBL] [Abstract][Full Text] [Related]
36. Impacts of human leukocyte antigen DQ genetic polymorphisms and their interactions with hepatitis B virus mutations on the risks of viral persistence, liver cirrhosis, and hepatocellular carcinoma.
Ji X; Zhang Q; Li B; Du Y; Yin J; Liu W; Zhang H; Cao G
Infect Genet Evol; 2014 Dec; 28():201-9. PubMed ID: 25281206
[TBL] [Abstract][Full Text] [Related]
37. Molecular mechanisms of HBV-associated hepatocarcinogenesis.
Guerrieri F; Belloni L; Pediconi N; Levrero M
Semin Liver Dis; 2013 May; 33(2):147-56. PubMed ID: 23749671
[TBL] [Abstract][Full Text] [Related]
38. Hepatitis B Virus and DNA Damage Response: Interactions and Consequences for the Infection.
Gómez-Moreno A; Garaigorta U
Viruses; 2017 Oct; 9(10):. PubMed ID: 29048354
[TBL] [Abstract][Full Text] [Related]
39. Roles of APOBEC3 in hepatitis B virus (HBV) infection and hepatocarcinogenesis.
Zhang Y; Chen X; Cao Y; Yang Z
Bioengineered; 2021 Dec; 12(1):2074-2086. PubMed ID: 34043485
[TBL] [Abstract][Full Text] [Related]
40. Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma.
Sukowati CH; El-Khobar KE; Ie SI; Anfuso B; Muljono DH; Tiribelli C
World J Gastroenterol; 2016 Jan; 22(4):1497-512. PubMed ID: 26819517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
